Chief Scientific Officer
Michael W. Dunne, MD is currently the Chief Science Officer at Iterum Therapeutics. He was previously the Chief Medical Officer of Durata Therapeutics, Inc. where he was responsible for the clinical development and regulatory submissions for dalbavancin. Prior to Durata, Michael was the Therapeutic Area Head for Infectious Diseases at Pfizer. Michael received his BA in Economics from Northwestern University. He subsequently received his MD from the SUNY Health Sciences Center, Brooklyn. He was a resident in Internal Medicine at Hartford Hospital and Yale New Haven Hospital and completed fellowship training at Yale in Infectious Diseases and Pulmonary Medicine.
Disclosure: Iterum Therapeutics (Employee, Shareholder)